NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - October 22, 2012) -
Regenerative medicine company Avita Medical Ltd.
(ASX: AVH), (OTCQX: AVMXY
) announced that further to Australian Stock Exchange announcements on 5 September 2012 and 16 October 2012 and following today's Shareholder Meeting it is pleased to announce the appointments of Jeremy Curnock Cook and Matt McNamara to the board of Avita Medical. The strengthening of Avita's board follows the company's successful capital raising of A$10.3m.
Avita Medical's Chairman, Dalton Gooding stated the appointments of Mr Curnock Cook and Mr McNamara further strengthen Avita's board.
"I am delighted that both Jeremy and Matt have been appointed as directors of Avita Medical and I extend a warm welcome on behalf of the board," Mr Gooding said.
"We look forward to drawing on the extensive experience that both Jeremy and Matt have in biotechnology and healthcare as we continue to increase our ReCell® Spray-On Skin® sales."
Mr Curnock Cook is currently on a number of boards of international healthcare and biotechnology companies. Jeremy is the former head of the life science private equity team at Rothschild Asset Management, was responsible for the launch of the first dedicated biotechnology fund for the Australian market and the launch of a joint venture with Johnson & Johnson Development Corporation for the creation of Healthcare Ventures, an investment vehicle dedicated to seed stage investments in Europe, as well as the conception and launch of the International Biotechnology Trust (IBT).
Mr McNamara is currently the Chief Investment Officer and Fund Manager of Octa Phillip Bioscience Managers. Matt has over 23 years experience in the healthcare & medical sciences sector. After initially being a molecular biology research assistant, Matt spent 11 years in Sales & Marketing and General Management with Merck & Co. and Johnson & Johnson Medical Pty. Ltd. respectively. He has served as SVP Business Development for a University of Sydney spin out, eBioinformatics Inc., and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty. Ltd.
The board would also like to thank Dr Paul Watt who has retired from the board of Avita Medical effective immediately. The board would like to acknowledge Dr Watt's extensive contribution that he has made over a 10 year period including 6 years as a director of pre-merger company Visiomed Limited. Dalton Gooding stated, "The board wishes Dr Watt all the very best and success with his future endeavors."
ABOUT AVITA MEDICAL LTD
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.